{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:22:00Z","timestamp":1793247720733,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02604-9","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T11:03:21Z","timestamp":1773399801000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Gut microbiota modulation via repeated donor fecal transplantation improves motor and gastrointestinal symptoms in drug-na\u00efve Parkinson\u2019s disease: a randomized phase 2 trial"],"prefix":"10.1038","volume":"11","author":[{"given":"Rui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renyi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfang","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beisha","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1205-982X","authenticated-orcid":false,"given":"Min","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsheng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1680-3639","authenticated-orcid":false,"given":"Erxi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebing","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"2604_CR1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adu6050","volume":"11","author":"R Kinet","year":"2025","unstructured":"Kinet, R. et al. Differential pathological dynamics triggered by distinct Parkinson patient-derived \u03b1-synuclein extracts in nonhuman primates. Sci. Adv. 11, eadu6050 (2025).","journal-title":"Sci. Adv."},{"key":"2604_CR2","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s13311-020-00889-4","volume":"17","author":"SD Aradi","year":"2020","unstructured":"Aradi, S. D. & Hauser, R. A. Medical management and prevention of motor complications in Parkinson\u2019s disease. Neurotherapeutics 17, 1339\u20131365 (2020).","journal-title":"Neurotherapeutics"},{"key":"2604_CR3","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s13311-020-00924-4","volume":"17","author":"MAC Sy","year":"2020","unstructured":"Sy, M. A. C. & Fernandez, H. H. Pharmacological treatment of early motor manifestations of Parkinson disease (PD). Neurotherapeutics 17, 1331\u20131338 (2020).","journal-title":"Neurotherapeutics"},{"key":"2604_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41531-023-00541-w","volume":"9","author":"C Rusch","year":"2023","unstructured":"Rusch, C., Flanagan, R., Suh, H. & Subramanian, I. To restrict or not to restrict? Practical considerations for optimizing dietary protein interactions on levodopa absorption in Parkinson\u2019s disease. NPJ Parkinsons Dis. 9, 98 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"2604_CR5","doi-asserted-by":"crossref","unstructured":"Green, J. E. et al. Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than Clostridium difficile infection: a systematic review and meta-analysis. Gut Microbes. 12, 1\u201325 (2020).","DOI":"10.1080\/19490976.2020.1854640"},{"key":"2604_CR6","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1080\/19490976.2020.1764309","volume":"11","author":"K Ka\u017amierczak-Siedlecka","year":"2020","unstructured":"Ka\u017amierczak-Siedlecka, K. et al. Therapeutic methods of gut microbiota modification in colorectal cancer management\u2014fecal microbiota transplantation, prebiotics, probiotics, and synbiotics. Gut Microbes. 11, 1518\u20131530 (2020).","journal-title":"Gut Microbes."},{"key":"2604_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41593-020-0589-7","volume":"23","author":"C Challis","year":"2020","unstructured":"Challis, C. et al. Gut-seeded \u03b1-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice. Nat. Neurosci. 23, 327\u2013336 (2020).","journal-title":"Nat. Neurosci."},{"key":"2604_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104887","volume":"98","author":"E Huh","year":"2023","unstructured":"Huh, E. et al. P. mirabilis-derived pore-forming haemolysin, HpmA drives intestinal alpha-synuclein aggregation in a mouse model of neurodegeneration. EBioMedicine 98, 104887 (2023).","journal-title":"EBioMedicine"},{"key":"2604_CR9","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41582-024-01016-z","volume":"20","author":"EE Smith","year":"2024","unstructured":"Smith, E. E. et al. Systemic determinants of brain health in ageing. Nat. Rev. Neurol. 20, 647\u2013659 (2024).","journal-title":"Nat. Rev. Neurol."},{"key":"2604_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41531-022-00295-x","volume":"8","author":"T Warnecke","year":"2022","unstructured":"Warnecke, T., Sch\u00e4fer, K. H., Claus, I., Del Tredici, K. & Jost, W. H. Gastrointestinal involvement in Parkinson\u2019s disease: pathophysiology, diagnosis, and management. NPJ Parkinsons Dis. 8, 31 (2022).","journal-title":"NPJ Parkinsons Dis."},{"key":"2604_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41392-023-01353-3","volume":"8","author":"X Dong-Chen","year":"2023","unstructured":"Dong-Chen, X., Yong, C., Yang, X., Chen-Yu, S. & Li-Hua, P. Signaling pathways in Parkinson\u2019s disease: molecular mechanisms and therapeutic interventions. Signal. Transduct. Target Ther. 8, 73 (2023).","journal-title":"Signal. Transduct. Target Ther."},{"key":"2604_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70012","volume":"5","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Gut microbiota in health and disease: advances and future prospects. MedComm (2020) 5, e70012 (2024).","journal-title":"MedComm (2020)"},{"key":"2604_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12934-021-01589-0","volume":"20","author":"X-Y Kuai","year":"2021","unstructured":"Kuai, X.-Y. et al. Evaluation of fecal microbiota transplantation in Parkinson\u2019s disease patients with constipation. Micro. Cell Fact. 20, 98 (2021).","journal-title":"Micro. Cell Fact."},{"key":"2604_CR14","doi-asserted-by":"publisher","first-page":"102563","DOI":"10.1016\/j.eclinm.2024.102563","volume":"71","author":"A Bruggeman","year":"2024","unstructured":"Bruggeman, A. et al. Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson\u2019s disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial. EClinicalMedicine 71, 102563 (2024).","journal-title":"EClinicalMedicine"},{"key":"2604_CR15","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1001\/jamaneurol.2024.2305","volume":"81","author":"F Scheperjans","year":"2024","unstructured":"Scheperjans, F. et al. Fecal microbiota transplantation for treatment of parkinson disease: a randomized clinical trial. JAMA Neurol. 81, 925\u2013938 (2024).","journal-title":"JAMA Neurol."},{"key":"2604_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1104759","volume":"14","author":"HL DuPont","year":"2023","unstructured":"DuPont, H. L. et al. Fecal microbiota transplantation in Parkinson\u2019s disease\u2014a randomized repeat-dose, placebo-controlled clinical pilot study. Front. Neurol. 14, 1104759 (2023).","journal-title":"Front. Neurol."},{"key":"2604_CR17","doi-asserted-by":"publisher","first-page":"2284247","DOI":"10.1080\/19490976.2023.2284247","volume":"15","author":"Y Cheng","year":"2023","unstructured":"Cheng, Y. et al. Efficacy of fecal microbiota transplantation in patients with Parkinson\u2019s disease: clinical trial results from a randomized, placebo-controlled design. Gut Microbes. 15, 2284247 (2023).","journal-title":"Gut Microbes."},{"key":"2604_CR18","doi-asserted-by":"publisher","first-page":"e2301097","DOI":"10.1002\/advs.202301097","volume":"10","author":"Y Yu","year":"2023","unstructured":"Yu, Y., Wang, W. & Zhang, F. The next generation fecal microbiota transplantation: to transplant bacteria or virome. Adv. Sci. 10, e2301097 (2023).","journal-title":"Adv. Sci."},{"key":"2604_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.parkreldis.2014.10.026","volume":"21","author":"P Mart\u00ednez-Mart\u00edn","year":"2014","unstructured":"Mart\u00ednez-Mart\u00edn, P. et al. Parkinson\u2019s disease severity levels and MDS-Unified Parkinson\u2019s Disease Rating Scale. Parkinsonism Relat. Disord. 21, 50\u201354 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"2604_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1001\/archneurol.2009.295","volume":"67","author":"LM Shulman","year":"2010","unstructured":"Shulman, L. M. et al. The clinically important difference on the Unified Parkinson\u2019s Disease Rating Scale. Arch. Neurol. 67, 64\u201370 (2010).","journal-title":"Arch. Neurol."},{"key":"2604_CR21","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.parkreldis.2015.10.006","volume":"21","author":"K Horv\u00e1th","year":"2015","unstructured":"Horv\u00e1th, K. et al. Minimal clinically important difference on the Motor Examination part of MDS-UPDRS. Parkinsonism Relat. Disord. 21, 1421\u20131426 (2015).","journal-title":"Parkinsonism Relat. Disord."},{"key":"2604_CR22","doi-asserted-by":"crossref","unstructured":"van der Kolk, N. M. et al. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson\u2019s disease: a double-blind, randomised controlled trial. Lancet Neurol. 18, 998\u20131008 (2019).","DOI":"10.1016\/S1474-4422(19)30285-6"},{"key":"2604_CR23","doi-asserted-by":"crossref","unstructured":"Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson\u2019s Disease Rating Scale (UPDRS): status and recommendations. Mov. Disord. 18, 738\u2013750 (2003).","DOI":"10.1002\/mds.10473"},{"key":"2604_CR24","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/mds.20913","volume":"21","author":"O Rascol","year":"2006","unstructured":"Rascol, O. Defining a minimal clinically relevant difference for the unified Parkinson\u2019s rating scale: an important but still unmet need. Mov. Disord. 21, 1059\u20131061 (2006).","journal-title":"Mov. Disord."},{"key":"2604_CR25","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1002\/mds.20914","volume":"21","author":"A Schrag","year":"2006","unstructured":"Schrag, A., Sampaio, C., Counsell, N. & Poewe, W. Minimal clinically important change on the unified Parkinson\u2019s disease rating scale. Mov. Disord. 21, 1200\u20131207 (2006).","journal-title":"Mov. Disord."},{"key":"2604_CR26","doi-asserted-by":"publisher","first-page":"101888","DOI":"10.1016\/j.eclinm.2023.101888","volume":"58","author":"H Tian","year":"2023","unstructured":"Tian, H. et al. Efficacy of faecal microbiota transplantation in patients with progressive supranuclear palsy-Richardson\u2019s syndrome: a phase 2, single centre, randomised clinical trial. EClinicalMedicine 58, 101888 (2023).","journal-title":"EClinicalMedicine"},{"key":"2604_CR27","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.parkreldis.2014.02.019","volume":"20","author":"AH Tan","year":"2014","unstructured":"Tan, A. H. et al. Small intestinal bacterial overgrowth in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 20, 535\u2013540 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"2604_CR28","doi-asserted-by":"crossref","unstructured":"Kim, S. et al. Transneuronal propagation of pathologic \u03b1-synuclein from the gut to the brain models Parkinson\u2019s disease. Neuron 103, 627\u2013641.e7 (2019).","DOI":"10.1016\/j.neuron.2019.05.035"},{"key":"2604_CR29","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1002\/mds.27326","volume":"33","author":"MC Houser","year":"2018","unstructured":"Houser, M. C. et al. Stool immune profiles evince gastrointestinal inflammation in Parkinson\u2019s disease. Mov. Disord. 33, 793\u2013804 (2018).","journal-title":"Mov. Disord."},{"key":"2604_CR30","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.parkreldis.2018.02.022","volume":"50","author":"A Schwiertz","year":"2018","unstructured":"Schwiertz, A. et al. Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 50, 104\u2013107 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"2604_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2276296","volume":"15","author":"D Liang","year":"2023","unstructured":"Liang, D. et al. Escherichia coli triggers \u03b1-synuclein pathology in the LRRK2 transgenic mouse model of PD. Gut Microbes. 15, 2276296 (2023).","journal-title":"Gut Microbes."},{"key":"2604_CR32","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41582-022-00681-2","volume":"18","author":"AH Tan","year":"2022","unstructured":"Tan, A. H., Lim, S. Y. & Lang, A. E. The microbiome-gut-brain axis in Parkinson disease\u2014from basic research to the clinic. Nat. Rev. Neurol. 18, 476\u2013495 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"2604_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40035-019-0146-z","volume":"8","author":"L Rota","year":"2019","unstructured":"Rota, L. et al. Constipation, deficit in colon contractions and alpha-synuclein inclusions within the colon precede motor abnormalities and neurodegeneration in the central nervous system in a mouse model of alpha-synucleinopathy. Transl. Neurodegener. 8, 5 (2019).","journal-title":"Transl. Neurodegener."},{"key":"2604_CR34","doi-asserted-by":"publisher","first-page":"e2030415","DOI":"10.1001\/jamanetworkopen.2020.30415","volume":"3","author":"KSW Leong","year":"2020","unstructured":"Leong, K. S. W. et al. Effects of fecal microbiome transfer in adolescents with obesity: the gut bugs randomized controlled trial. JAMA Netw. Open 3, e2030415 (2020).","journal-title":"JAMA Netw. Open"},{"key":"2604_CR35","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/s41591-021-01399-2","volume":"27","author":"V Mocanu","year":"2021","unstructured":"Mocanu, V. et al. Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial. Nat. Med. 27, 1272\u20131279 (2021).","journal-title":"Nat. Med."},{"key":"2604_CR36","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2021.2020067","volume":"14","author":"P Singh","year":"2022","unstructured":"Singh, P. et al. Effect of antibiotic pretreatment on bacterial engraftment after Fecal Microbiota Transplant (FMT) in IBS-D. Gut Microbes. 14, 2020067 (2022).","journal-title":"Gut Microbes."},{"key":"2604_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jare.2022.12.001","volume":"53","author":"S Mitra","year":"2022","unstructured":"Mitra, S., Dash, R., Nishan, A. A., Habiba, S. U. & Moon, I. S. Brain modulation by the gut microbiota: From disease to therapy. J. Adv. Res. 53, 153\u2013173 (2022).","journal-title":"J. Adv. Res."},{"key":"2604_CR38","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/gutjnl-2019-319630","volume":"69","author":"M El-Salhy","year":"2020","unstructured":"El-Salhy, M., Hatlebakk, J. G., Gilja, O. H., Br\u00e5then Kristoffersen, A. & Hausken, T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut 69, 859\u2013867 (2020).","journal-title":"Gut"},{"key":"2604_CR39","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1136\/gutjnl-2016-313017","volume":"66","author":"G Cammarota","year":"2017","unstructured":"Cammarota, G. et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 66, 569\u2013580 (2017).","journal-title":"Gut"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02604-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02604-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02604-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T11:03:23Z","timestamp":1773399803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02604-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2604"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02604-9","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Min Wu is a member of the Editorial Board of\n                      Signal Transduction and Targeted Therapy\n                      . To avoid any potential conflict of interest, he was not involved in the journal\u2019s editorial review of this manuscript. All other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}